Published in Cancer Res on June 23, 2009
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (2011) 5.98
The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol (2010) 4.26
From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer (2009) 4.15
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood (2015) 3.47
The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood (2012) 2.39
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol (2013) 1.66
STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc Natl Acad Sci U S A (2010) 1.55
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. Cancer Cell (2015) 1.52
Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res (2013) 1.51
Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov (2013) 1.39
Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum (2010) 1.26
Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol Sci (2014) 1.10
Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol (2010) 1.07
The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions. Front Immunol (2012) 0.95
Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas. J Biol Chem (2011) 0.94
Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells. PLoS One (2011) 0.94
How will B-cell-receptor-targeted therapies change future CLL therapy? Blood (2014) 0.90
Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer. Biochim Biophys Acta (2014) 0.89
Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer. BMC Syst Biol (2013) 0.89
p110δ PI3 kinase pathway: emerging roles in cancer. Front Oncol (2013) 0.89
The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene (2015) 0.87
Syk interacts with and phosphorylates nucleolin to stabilize Bcl-x(L) mRNA and promote cell survival. Mol Cell Biol (2014) 0.84
Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. Curr Opin Hematol (2014) 0.83
RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia. Oncotarget (2015) 0.83
Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget (2016) 0.83
Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14. PLoS One (2012) 0.83
Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL. Mediterr J Hematol Infect Dis (2012) 0.82
The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies. Oncogene (2013) 0.82
Metadherin contribute to BCR signaling in chronic lymphocytic leukemia. Int J Clin Exp Pathol (2014) 0.81
Critical signal transduction pathways in CLL. Adv Exp Med Biol (2013) 0.81
Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder. Pediatr Transplant (2012) 0.81
Syk inhibits the activity of protein kinase A by phosphorylating tyrosine 330 of the catalytic subunit. J Biol Chem (2013) 0.79
Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma. Exp Hematol Oncol (2015) 0.79
Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia. Exp Hematol (2010) 0.79
Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder. Am J Transplant (2013) 0.78
Modulation by Syk of Bcl-2, calcium and the calpain-calpastatin proteolytic system in human breast cancer cells. Biochim Biophys Acta (2013) 0.78
Multidimensional single-cell analysis of BCR signaling reveals proximal activation defect as a hallmark of chronic lymphocytic leukemia B cells. PLoS One (2014) 0.78
CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans. PLoS Med (2015) 0.78
Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice. Blood Cancer J (2014) 0.77
Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling. Cell Death Dis (2014) 0.77
Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia. PLoS One (2016) 0.75
Fostamatinib Disodium. Drugs Future (2011) 0.75
Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia. Expert Opin Investig Drugs (2012) 0.75
ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy. Oncotarget (2016) 0.75
Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. Oncotarget (2016) 0.75
Basal Ca(2+) signaling is particularly increased in mutated chronic lymphocytic leukemia. Leukemia (2014) 0.75
Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib. Ther Adv Hematol (2016) 0.75
Identification of distinct molecular subtypes of uterine carcinosarcoma. Oncotarget (2017) 0.75
Does B cell receptor signaling in chronic lymphocytic leukaemia cells differ from that in other B cell types? Scientifica (Cairo) (2014) 0.75
Modulation of B-cell receptor and microenvironment signaling by a guanine exchange factor in B-cell malignancies. Cancer Biol Med (2016) 0.75
Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma. J Hematol Oncol (2017) 0.75
Targeting B Cell Signaling in Chronic Lymphocytic Leukemia. Curr Oncol Rep (2017) 0.75
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget (2017) 0.75
Syk inhibitors in clinical development for hematological malignancies. J Hematol Oncol (2017) 0.75
Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med (2009) 7.53
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med (2009) 5.20
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 3.89
The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity (2012) 3.65
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature (2010) 3.39
WNT and DKK determine hair follicle spacing through a reaction-diffusion mechanism. Science (2006) 3.36
Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology (2012) 3.28
Design principles of a bacterial signalling network. Nature (2005) 3.28
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood (2008) 3.19
Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol (2009) 3.13
Yin Yang 1 is a critical regulator of B-cell development. Genes Dev (2007) 3.06
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol (2005) 3.05
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell (2008) 3.01
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood (2010) 2.72
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits. Immunity (2007) 2.65
Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med (2007) 2.62
Systems biology: experimental design. FEBS J (2009) 2.44
The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell (2009) 2.42
Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺ CD4⁺ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity (2013) 2.37
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood (2012) 2.37
Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood (2006) 2.36
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature (2012) 2.36
The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion. Nat Immunol (2002) 2.35
SLP-65 regulates immunoglobulin light chain gene recombination through the PI(3)K-PKB-Foxo pathway. Nat Immunol (2008) 2.29
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol (2011) 2.26
Dynamical modeling and multi-experiment fitting with PottersWheel. Bioinformatics (2008) 2.22
Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat Rev Immunol (2009) 2.19
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest (2005) 2.15
Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. Br J Haematol (2013) 2.06
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood (2010) 2.04
Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood (2004) 2.01
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol (2002) 1.98
Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS. Nat Neurosci (2011) 1.96
Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet (2012) 1.94
FLT3 mutations in childhood acute lymphoblastic leukemia. Blood (2003) 1.91
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood (2008) 1.90
CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene (2005) 1.87
The phenotype of human STK4 deficiency. Blood (2012) 1.84
Control of plant organ size by KLUH/CYP78A5-dependent intercellular signaling. Dev Cell (2007) 1.80
Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med (2009) 1.80
Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis (2006) 1.78
Systems-level interactions between insulin-EGF networks amplify mitogenic signaling. Mol Syst Biol (2009) 1.77
Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol (2006) 1.68
Oscillatory cerebral hemodynamics--the macro- vs. microvascular level. J Neurol Sci (2006) 1.67
Covering a broad dynamic range: information processing at the erythropoietin receptor. Science (2010) 1.65
Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol (2013) 1.63
CD40L induces inflammation and adipogenesis in adipose cells--a potential link between metabolic and cardiovascular disease. Thromb Haemost (2010) 1.63
Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol (2007) 1.62
The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood (2013) 1.62
Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma. Blood (2010) 1.62
Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100. Blood (2013) 1.62
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A (2009) 1.61
Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood (2013) 1.61
SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. Blood (2011) 1.57
BCL6 is critical for the development of a diverse primary B cell repertoire. J Exp Med (2010) 1.56
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol (2012) 1.56
CXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis). Br J Haematol (2003) 1.56
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol (2012) 1.55
Molecular fingerprinting of the podocyte reveals novel gene and protein regulatory networks. Kidney Int (2013) 1.55
Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood (2007) 1.53
Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med (2009) 1.52
Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest (2009) 1.49
Bilateral renal lymphoma after paraneoplastic limbic encephalitis. J Clin Oncol (2009) 1.47
The role of B7 family molecules in hematologic malignancy. Blood (2012) 1.47
Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. J Exp Med (2007) 1.47
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med (2011) 1.45
Likelihood based observability analysis and confidence intervals for predictions of dynamic models. BMC Syst Biol (2012) 1.45
Division of labor by dual feedback regulators controls JAK2/STAT5 signaling over broad ligand range. Mol Syst Biol (2011) 1.45
A common strategy and database to compare the performance of seizure prediction algorithms. Epilepsy Behav (2009) 1.43
Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res (2008) 1.42
Hybrid optimization method with general switching strategy for parameter estimation. BMC Syst Biol (2008) 1.41
Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood (2012) 1.41
Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer (2010) 1.40
HAX1 mutations causing severe congenital neuropenia and neurological disease lead to cerebral microstructural abnormalities documented by quantitative MRI. Am J Med Genet A (2010) 1.40
Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J Exp Med (2013) 1.39
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant (2006) 1.34
Reconstructing gene-regulatory networks from time series, knock-out data, and prior knowledge. BMC Syst Biol (2007) 1.34
Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology (2013) 1.32
A quantitative and dynamic model for plant stem cell regulation. PLoS One (2008) 1.32